Rice Bran Lipid Formulation for Selective Gene Delivery to Cancer Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including chemotherapy and radiation, often result in incomplete cell killing and drug resistance, leading to recurrence, and non-viral gene delivery methods lack specificity and efficiency in targeting cancer cells without harming normal cells.
Innovation Solution
A rice bran-lipids based formulation using glycolipids and phospholipids in combination with cationic lipids and cholesterol is developed for selective delivery of genes to cancer cells, enhancing transfection efficiency and specificity by exploiting the affinity of these lipids to cancer cell surface receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If non-viral gene delivery methods are used, then safety and reduced toxicity are improved, but transfection efficiency and specificity to cancer cells deteriorate
Solution Approach 1:
The patent applies local quality by incorporating rice bran glycolipids and phospholipids specifically into the liposomal formulation to target cancer cell surface receptors. This localized modification of the delivery vehicle enables selective interaction with cancer cells while maintaining safety for normal cells, thereby improving both transfection efficiency and specificity without compromising the safety advantage of non-viral methods.
Solution Approach 2:
The patent uses composite materials by combining rice bran glycolipids, phospholipids, and cationic lipids in a liposomal formulation. This composite structure leverages the specific affinity of rice bran lipids for cancer cell receptors while maintaining the biocompatibility of phospholipids and the transfection capability of cationic lipids, thereby achieving enhanced transfection efficiency without increasing toxicity.
2Productivity
If conventional cancer treatments (chemotherapy and radiation) are used, then tumor growth blocking is improved, but cell killing completeness and drug resistance deteriorate
Solution Approach 1:
The patent employs gene delivery vectors as intermediaries to introduce therapeutic genes into cancer cells. This intermediary approach allows for the delivery of genes that can overcome drug resistance mechanisms and enhance cell killing completeness, addressing the limitations of conventional treatments while maintaining their tumor growth blocking effectiveness.
3Measurement precision
If rice bran glycolipids and phospholipids are incorporated into the formulation, then transfection specificity to cancer cells is improved, but formulation complexity increases
Solution Approach 1:
The patent applies universality by using rice bran glycolipids and phospholipids that serve multiple functions: they provide cancer cell targeting specificity, maintain formulation stability, and enhance transfection efficiency. This multi-functionality reduces the need for additional separate components, thereby limiting the increase in formulation complexity while achieving improved transfection specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves significant and specific gene transfection in breast and lung cancer cells while minimizing transfection in non-cancerous cells, potentially leading to more effective cancer treatment with reduced toxicity to normal cells.
Implementation Method 1
enhancing the transfection efficiency of the formulation; and (d) a gene or genetic products of interest
Implementation Method 2
A rice bran-lipids based formulation using glycolipids and phospholipids in combination with cationic lipids
Data Source
AI summary
The present invention relates to a formulation in which glycolipids and phospholipids, isolated from rice bran gum samples, were used in conjunction with gene carrying lipids to test its efficacy in delivering genes to cancer cells selectively. This formulation did not mediate efficient delivery of genes to non-cancerous cells, thus, showing potential use of this formulation to deliver anticancer therapeutics to cancer cells without eliciting treatment related toxicity to normal cells.